Levormeloxifene

Levormeloxifene
Clinical data
Synonyms	Levomeloxifene; 6720-CDRI; NNC-460020
Identifiers
	IUPAC name 1-(2-[4-[(3R,4R)-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy]ethyl)pyrrolidine;
CAS Number	31477-60-8 ;
PubChem CID	35805;
ChemSpider	32935 ;
UNII	9512UKZ352;
ChEMBL	CHEMBL301327 ;
Chemical and physical data
Formula	C30H35NO3
Molar mass	457.604 g/mol
3D model (JSmol)	Interactive image;
	SMILES O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5;
	InChI InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 ; Key:XZEUAXYWNKYKPL-WDYNHAJCSA-N ;
(what is this?) (verify)

Levormeloxifene (INN; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed.^[1] The development was stopped because of a high incidence of gynecological side effects during clinical trials.^[2] Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.

References

↑ http://adisinsight.springer.com/drugs/800000737
↑ Ravn P, Nielsen TF, Christiansen C (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. PMID 16532904.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.